This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2021 Jul 10;3(1):vdab095.

doi: 10.1093/noajnl/vdab095. eCollection 2021 Jan-Dec.

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

Iyad Alnahhas¹, Mouaz Alsawas², Appaji Rayi³, Joshua D Palmer⁴, Raju Raval⁴, Shirley Ong³, Pierre Giglio³, Mohammad Hassan Murad², Vinay Puduvalli³

Affiliations

Affiliations

¹ Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
² Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
³ Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁴ Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

PMID: 34258581
PMCID: PMC8272530
DOI: 10.1093/noajnl/vdab095

Published Erratum

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

Iyad Alnahhas et al. Neurooncol Adv. 2021.

. 2021 Jul 10;3(1):vdab095.

doi: 10.1093/noajnl/vdab095. eCollection 2021 Jan-Dec.

Authors

Iyad Alnahhas¹, Mouaz Alsawas², Appaji Rayi³, Joshua D Palmer⁴, Raju Raval⁴, Shirley Ong³, Pierre Giglio³, Mohammad Hassan Murad², Vinay Puduvalli³

Affiliations

¹ Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
² Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
³ Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁴ Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

PMID: 34258581
PMCID: PMC8272530
DOI: 10.1093/noajnl/vdab095

Abstract

[This corrects the article DOI: 10.1093/noajnl/vdaa082.].

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

PubMed Disclaimer

Erratum for

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.
Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V. Alnahhas I, et al. Neurooncol Adv. 2020 Oct 30;2(1):vdaa082. doi: 10.1093/noajnl/vdaa082. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33150334 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program